Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products

BACKGROUND: BAY 81–8973 (Kovaltry) is an unmodified full-length recombinant factor VIII (rFVIII) for treatment of hemophilia A. The BAY 81–8973 manufacturing process results in a product of enhanced purity with a consistently high degree of branching and sialylation of N-linked glycans. This study e...

Descripción completa

Detalles Bibliográficos
Autores principales: Teare, John M, Kates, David S, Shah, Anita, Garger, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435118/
https://www.ncbi.nlm.nih.gov/pubmed/30962676
http://dx.doi.org/10.2147/DDDT.S188171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435118/
https://www.ncbi.nlm.nih.gov/pubmed/30962676
http://dx.doi.org/10.2147/DDDT.S188171

Ejemplares similares